Replimune (REPL) Interest Coverage Ratio (2019 - 2025)
Replimune's (REPL) quarterly Interest Coverage Ratio came in at 49.02 in Q4 2025, down 7.67% year-on-year from 53.1 in Q4 2024, and up 13.46% quarter-over-quarter from 56.65 in Q3 2025.
Replimune (REPL) Interest Coverage Ratio (2019 - 2025) Analysis & Trends
Replimune has disclosed Interest Coverage Ratio across 7 years of filings, most recently posting 49.02 for Q4 2025.
- Interest Coverage Ratio for Q4 2025 came in at 49.02, down 7.67% year-over-year; the trailing twelve-month figure through Dec 2025 was 55.33 (down 31.48% YoY), and the FY2025 annual result was 45.3, up 13.22% from the prior year.
- Interest Coverage Ratio came in at 49.02 for Q4 2025 at Replimune, up from 56.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 40.23 in Q2 2024 to a low of 22184.0 in Q1 2021.
- The 5-year median for Interest Coverage Ratio is 50.88 (2023), against an average of 1631.59.
- Across the five-year window, Interest Coverage Ratio sank 40040.68% in 2021 and jumped 38.7% in 2024, its largest moves.
- Replimune's Interest Coverage Ratio stood at 22184.0 in 2021, then soared by 99.8% to 44.24 in 2022, then declined by 26.29% to 55.87 in 2023, then rose by 18.51% to 45.53 in 2024, then retreated by 7.67% to 49.02 in 2025.
- The last three Interest Coverage Ratio figures came in at 49.02 (Q4 2025), 56.65 (Q3 2025), and 61.3 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -258.33 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 11.79 |
| 10 | Replimune | 848.00 Mn | 578.86 Mn | - | -49.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -49.02 |
| Sep 30, 2025 | -56.65 |
| Jun 30, 2025 | -61.30 |
| Mar 31, 2025 | -54.30 |
| Dec 31, 2024 | -45.53 |
| Sep 30, 2024 | -40.97 |
| Jun 30, 2024 | -40.23 |
| Mar 31, 2024 | -41.55 |
| Dec 31, 2023 | -55.87 |
| Sep 30, 2023 | -66.84 |
| Jun 30, 2023 | -49.91 |
| Mar 31, 2023 | -51.85 |
| Dec 31, 2022 | -44.24 |
| Mar 31, 2021 | -22,184.00 |
| Dec 31, 2020 | -82.09 |
| Sep 30, 2020 | -68.75 |
| Jun 30, 2020 | -62.79 |
| Mar 31, 2020 | 55.54 |
| Dec 31, 2019 | -19.98 |
| Sep 30, 2019 | -62.78 |